169 related articles for article (PubMed ID: 36059465)
1. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
Front Immunol; 2022; 13():974188. PubMed ID: 36059465
[TBL] [Abstract][Full Text] [Related]
2. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
3. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.
Carmenate T; Pacios A; Enamorado M; Moreno E; Garcia-Martínez K; Fuente D; León K
J Immunol; 2013 Jun; 190(12):6230-8. PubMed ID: 23677467
[TBL] [Abstract][Full Text] [Related]
4. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
5. A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.
Casadesús AV; Deligne C; Diallo BK; Sosa K; Josseaume N; Mesa C; León K; Hernández T; Teillaud JL
Oncoimmunology; 2020 Jun; 9(1):1770565. PubMed ID: 32923126
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract][Full Text] [Related]
7. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
LaPorte KM; Hernandez R; Santos Savio A; Malek TR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
[TBL] [Abstract][Full Text] [Related]
8. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
[TBL] [Abstract][Full Text] [Related]
9. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G
Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.
Pham MN; Khoryati L; Jamison BL; Hayes E; Sullivan JM; Campbell DJ; Gavin MA
Immunohorizons; 2021 Sep; 5(9):782-791. PubMed ID: 34583939
[TBL] [Abstract][Full Text] [Related]
11. Combining computational and experimental biology to develop therapeutically valuable IL2 muteins.
León K; García-Martínez K; Carmenate T; Rojas G
Semin Oncol; 2018 Jan; 45(1-2):95-104. PubMed ID: 30318089
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
13. MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.
Kobayashi M; Kojima K; Murayama K; Amano Y; Koyama T; Ogama N; Takeshita T; Fukuhara T; Tanaka N
Cancer Sci; 2021 Nov; 112(11):4478-4489. PubMed ID: 34545658
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating mast cells stimulate ICOS
Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
[TBL] [Abstract][Full Text] [Related]
15. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract][Full Text] [Related]
16. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
17. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R.
Zhao J; Zhao J; Perlman S
PLoS One; 2012; 7(9):e46241. PubMed ID: 23029447
[TBL] [Abstract][Full Text] [Related]
19. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
20. Endogenous IL-33 exerts CD8
Xia Y; Ohno T; Nishii N; Bhingare A; Tachinami H; Kashima Y; Nagai S; Saito H; Nakae S; Azuma M
Biochem Biophys Res Commun; 2019 Oct; 518(2):331-336. PubMed ID: 31421832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]